Lilly’s Zepbound Resolves Sleep Apnea in 52% of Patients
Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
- Latest
- Trending
Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
AbbVie sets quarterly dividend at $1.55 per share, showcasing financial health and strategic growth. Recent acquisitions bolster positive outlook.
Gov. Roy Cooper vetoes bill banning public face masks and changing campaign finance laws, citing concerns over secret campaign money ...
Gov. Cooper vetoes bill altering NC's campaign finance, protest penalties, and mask rules; sparks debate on billionaire influence in elections.
AI is revolutionizing healthcare, finance, and more, say NVIDIA's Trivedi and Uniphore's Sachdev, showcasing efficiency and cost savings across sectors.
Jazz Pharmaceuticals hits a hurdle as its essential tremor drug trial misses primary endpoint. Awaiting Parkinson's trial results for future ...
Trinity Biotech plc gets a "buy" rating from StockNews.com analysts, spotlighting potential for investors with a focus on its diagnostic ...
Boston Scientific to acquire Silk Road Medical for $1.16B, boosting Silk Road shares by 24%. Expected to finalize by H2 ...
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.